Scarica l'app Stockscreener
5.60
3.95%
-0.23
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$5.83
Aprire:
$5.84
Volume 24 ore:
1.44M
Relative Volume:
0.59
Capitalizzazione di mercato:
$1.14B
Reddito:
-
Utile/perdita netta:
$-54.70M
Rapporto P/E:
-16.97
EPS:
-0.33
Flusso di cassa netto:
$-51.36M
1 W Prestazione:
+5.66%
1M Prestazione:
-5.41%
6M Prestazione:
+107.41%
1 anno Prestazione:
+97.88%
Intervallo 1D:
$5.57
$6.06
Intervallo di 1 settimana:
$5.095
$6.06
Portata 52W:
$1.89
$7.005
Savara Inc Stock (SVRA) Company Profile
Nome
Savara Inc
Settore
Industria
Telefono
51285113796
Indirizzo
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
5.60 | 1.19B | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-08-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-05-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-12-20 | Iniziato | Wells Fargo | Overweight |
| 2024-11-13 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-15 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-11-07 | Iniziato | Guggenheim | Buy |
| 2023-05-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-31 | Downgrade | Jefferies | Buy → Hold |
| 2021-03-16 | Iniziato | Piper Sandler | Overweight |
| 2021-03-15 | Iniziato | Oppenheimer | Outperform |
| 2019-06-13 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-13 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | Ripresa | ROTH Capital | Neutral |
| 2018-01-03 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-09-27 | Ripresa | ROTH Capital | Buy |
| 2017-09-22 | Iniziato | Jefferies | Buy |
| 2017-09-11 | Iniziato | JMP Securities | Mkt Outperform |
Mostra tutto
Savara Inc Borsa (SVRA) Ultime notizie
What dividend safety score for Savara Inc. stockEarnings Growth Report & Safe Entry Point Identification - mfd.ru
Savara Announces New Employment Inducement Grant - The Joplin Globe
Savara (NASDAQ:SVRA) Shares Up 6.8%Here's Why - MarketBeat
Growth Value: Is Savara Inc being accumulated by smart moneyEarnings Trend Report & Verified Trade Idea Suggestions - baoquankhu1.vn
Savara Insiders Added US$535.6k Of Stock To Their Holdings - Yahoo Finance
Savara Secures Path to $150M as FDA Decision Nears for Rare Lung Drug - MyChesCo
Savara Announces Participation in Upcoming February 2026 Investor Healthcare Conferences - BioSpace
Savara Inc. (NASDAQ:SVRA) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Savara Announces Participation in Upcoming Investor Healthcare Conferences - ChartMill
Savara Inc. Launches Convenient DBS Test for Diagnosing Rare Lung Disease - MSN
Savara (NASDAQ:SVRA) Trading 2.5% HigherShould You Buy? - MarketBeat
Expanded Hercules Credit Line Tied To MOLBREEVI Approval Could Be A Game Changer For Savara (SVRA) - simplywall.st
ETF Watch: Why is Savara Inc stock going downQuarterly Performance Summary & Stock Timing and Entry Methods - baoquankhu1.vn
Savara grants equity awards to new hires as it advances rare lung drug - MSN
Growth Report: Is Savara Inc being accumulated by smart moneyQuarterly Profit Review & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Movement Recap: Will Savara Inc announce a stock splitStock Surge & AI Enhanced Execution Alerts - baoquankhu1.vn
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI - BioSpace
Savara secures additional $75m in debt financing for potential drug launch - Investing.com Australia
Hercules Capital Ties Savara Funding To FDA Milestone And Valuation Case - simplywall.st
A Look At Hercules Capital (HTGC) Valuation After The Expanded Savara Loan Agreement - Yahoo Finance
Savara Reports Amendment to Hercules Capital Debt Facility - marketscreener.com
Savara amends loan agreement to access up to $105 million in term loans - Investing.com Nigeria
Savara Grants Equity Awards to New Hires as It Advances Rare Lung Drug - MyChesCo
How Investors May Respond To Savara (SVRA) Adding Approval-Linked Hercules Credit To Its Liquidity Toolkit - simplywall.st
Savara Ekes up on Deal with Hercules - Baystreet.ca
Savara amends loan agreement to access up to $105 million in term loans By Investing.com - Investing.com South Africa
Savara Enters New Material Definitive Agreement and Obligation - TipRanks
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI* - Business Wire
Savara (SVRA) Faces Class Action Lawsuit Over Shareholder Losses - Intellectia AI
SAVARA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Savara, Inc. (SVRA) Stock Analysis: Exploring a 67% Potential Upside in Rare Respiratory Disease Biotech - DirectorsTalk Interviews
CEO Moves: Does Star Equity Holdings Inc have a competitive edgeLong Setup & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Rare lung drug nears FDA decision as PANTHERx, Savara seal US deal - MSN
Rare Lung Drug Nears FDA Decision as PANTHERx, Savara Seal U.S. Deal - mychesco.com
Savara Secures $75 Million Royalty Deal to Back Potential MOLBREEVI Launch - MSN
FDA clock restarts: Savara refiles MOLBREEVI for rare lung disease - MSN
Day Trade: What is the dividend yield of LIVEJuly 2025 Breakouts & Risk Managed Investment Strategies - baoquankhu1.vn
Aug Opening: Should I trade or invest in Savara Inc2025 Institutional Moves & AI Forecast for Swing Trade Picks - baoquankhu1.vn
What Savara (SVRA)'s Exclusive PANTHERx MOLBREEVI Distribution Deal Means For Shareholders - simplywall.st
Aug Opening: Will Savara Inc benefit from government policyRate Cut & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Savara Reports 2024 Financial Results and Provides Updates on MOLBREEVI Progress - MSN
Value Recap: Can Savara Inc disrupt its industryJobs Report & Weekly Watchlist of Top Performers - baoquankhu1.vn
Savara Highlights Autoimmune PAP Burden in Updated Presentation - TipRanks
Lobbying Update: $30,000 of SAVARA INC. lobbying was just disclosed | SVRA Stock News - Quiver Quantitative
With 37% stake, Savara Inc. (NASDAQ:SVRA) seems to have captured institutional investors' interest - Yahoo Finance
Savara Inc. (NASDAQ:SVRA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Savara Inc. Announces Equity Awards for New Employees - MSN
Savara Inc. Grants Inducement Awards to New Employees with Stock Options & RSUs - msn.com
How big funds are accumulating Savara Inc. (YB4P) stock2025 Price Action Summary & Capital Protection Trade Alerts - Улправда
Why Savara Inc. stock is favored by top institutions2025 Stock Rankings & Growth Focused Entry Reports - ulpravda.ru
How Savara Inc. stock compares to growth peers2025 Institutional Moves & AI Optimized Trading Strategy Guides - Улправда
Savara Inc Azioni (SVRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):